Elias Sanidas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elias Sanidas has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
John Barbetseas
Department of Cardiology, Laiko General Hospital, Athens, Greece
18 shared publicationsMaria Velliou
Department of Emergency Medicine, “Attikon” University Hospital, Athens, Greece
11 shared publicationsDimitrios Papadopoulos
Department of Cardiology, Laiko General Hospital, Athens, Greece
6 shared publicationsKonstantinos Toutouzas
1(st) University Department of Cardiology, "Hippokration" General Hospital, Athens, Greece
5 shared publicationsVasilios Papademetriou
Hypertension and Cardiovascular Research Clinic, Veterans Affairs and Georgetown University Medical Centers, Washington, DC, USA
5 shared publicationsCharalampos Grassos
Department of Cardiology, General Oncology Hospital "Oi Agioi Anargiroi", Kifisia, Greece
4 shared publications
Latest Publications
- 14 March 2026
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 150, 106831
Resting Heart Rate: a risk marker or factor for outcomes?
- 14 March 2026
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 150, 106831
Resting Heart Rate: a risk marker or factor for outcomes?
- Open Access
- 2 March 2026
- Published by Elsevier in Hellenic Journal of Cardiology
Rethinking Cardiac Arrest: New Paradigms in the 2025 ERC Guidelines
- 2 March 2026
- Published by Elsevier in Hellenic Journal of Cardiology
Open AccessRethinking Cardiac Arrest: New Paradigms in the 2025 ERC Guidelines
- Open Access
- 23 August 2025
- Vol. 13 (1)
The Role of Point-of-care Ultrasound in Cardiac Arrest; A Narrative Review
Cardiac arrest is a life-threatening condition with a high mortality rate, necessitating prompt recognition and treatment of reversible causes to enhance patient survival. Point-of-care ultrasound (POCUS) has emerged as a useful tool that contributes to optimizing resuscitative efforts. This imaging modality offers real-time visualization that assists in detecting reversible causes such as cardiac tamponade, pulmonary embolism, tension pneumothorax and hypovolemia. This review aims to explore the expanding role of ultrasound in the assessment and management of cardiac arrest, emphasizing its utility in identifying cardiac arrest, differentiating between true pulseless electrical activity (PEA) and pseudo-PEA, detecting the reversible causes, guiding clinical decision-making, and potentially predicting outcomes. A comprehensive literature search was performed using the PubMed database from inception to April 2025. Articles were selected based on their relevance to the role and applications of POCUS in cardiac arrest.
- 23 August 2025
- Vol. 13 (1)
Open AccessThe Role of Point-of-care Ultrasound in Cardiac Arrest; A Narrative Review
Cardiac arrest is a life-threatening condition with a high mortality rate, necessitating prompt recognition and treatment of reversible causes to enhance patient survival. Point-of-care ultrasound (POCUS) has emerged as a useful tool that contributes to optimizing resuscitative efforts. This imaging modality offers real-time visualization that assists in detecting reversible causes such as cardiac tamponade, pulmonary embolism, tension pneumothorax and hypovolemia. This review aims to explore the expanding role of ultrasound in the assessment and management of cardiac arrest, emphasizing its utility in identifying cardiac arrest, differentiating between true pulseless electrical activity (PEA) and pseudo-PEA, detecting the reversible causes, guiding clinical decision-making, and potentially predicting outcomes. A comprehensive literature search was performed using the PubMed database from inception to April 2025. Articles were selected based on their relevance to the role and applications of POCUS in cardiac arrest.
- Open Access
Update on Thromboembolic Events After Vaccination Against COVID-19
The association between COVID-19 vaccination and thromboembolic events has garnered significant research attention, particularly with the advent of vaccines based on adenoviral vectors, including AstraZeneca’s and Johnson & Johnson’s vaccines. This review underscores the uncommon occurrence of venous thromboembolism (VTE), arterial thromboembolism (ATE), and vaccine-induced thrombotic thrombocytopenia (VITT) following COVID-19 vaccination. Although these complications are extremely rare compared to the heightened risk of thrombosis from COVID-19 infection, elements like age, biological sex, type of vaccine and underlying health conditions may contribute to their development. In addition, rare renal complications such as acute kidney injury and thrombotic microangiopathy have been documented, broadening the spectrum of potential vaccine-associated thrombotic manifestations. Current guidelines emphasize early detection, individualized risk assessment, and use of anticoagulation therapy to mitigate risks. Despite these events, the overwhelming majority of evidence supports the continued use of COVID-19 vaccines, given their proven efficacy in reducing severe illness and mortality. In addition, recent comparative data confirm that mRNA-based vaccines are associated with a significantly lower risk of serious thrombotic events compared to adenoviral vector platforms. Ongoing research is essential to further refine preventive and therapeutic strategies, particularly for at-risk populations.
Open AccessUpdate on Thromboembolic Events After Vaccination Against COVID-19
The association between COVID-19 vaccination and thromboembolic events has garnered significant research attention, particularly with the advent of vaccines based on adenoviral vectors, including AstraZeneca’s and Johnson & Johnson’s vaccines. This review underscores the uncommon occurrence of venous thromboembolism (VTE), arterial thromboembolism (ATE), and vaccine-induced thrombotic thrombocytopenia (VITT) following COVID-19 vaccination. Although these complications are extremely rare compared to the heightened risk of thrombosis from COVID-19 infection, elements like age, biological sex, type of vaccine and underlying health conditions may contribute to their development. In addition, rare renal complications such as acute kidney injury and thrombotic microangiopathy have been documented, broadening the spectrum of potential vaccine-associated thrombotic manifestations. Current guidelines emphasize early detection, individualized risk assessment, and use of anticoagulation therapy to mitigate risks. Despite these events, the overwhelming majority of evidence supports the continued use of COVID-19 vaccines, given their proven efficacy in reducing severe illness and mortality. In addition, recent comparative data confirm that mRNA-based vaccines are associated with a significantly lower risk of serious thrombotic events compared to adenoviral vector platforms. Ongoing research is essential to further refine preventive and therapeutic strategies, particularly for at-risk populations.
- Open Access
- 8 July 2025
- Published by MDPI AG in Preprints.org
Update on the Thromboembolic Events After Vaccination Against COVID 19
The association between COVID-19 vaccination and thromboembolic events has gar-nered significant research attention, particularly with the advent of vaccines based on adenoviral vectors, including AstraZeneca's and Johnson & Johnson's. This review un-derscores the uncommon occurrence of blood clotting events, including venous throm-boembolism (VTE), arterial thromboembolism (ATE), and vaccine-induced thrombotic thrombocytopenia (VITT), following COVID-19 vaccination. Although these complica-tions are extremely rare compared to the heightened risk of thrombosis from COVID-19 infection, elements like age, biological sex, type of vaccine and underlying health conditions may contribute to their development. Current guidelines emphasize early detection, individualized risk assessment, and the use of anticoagulation therapy to mitigate risks. Despite these rare events, the overwhelming evidence supports the con-tinued use of COVID-19 vaccines, given their proven efficacy in reducing severe illness and mortality. Ongoing research is essential to further refine preventive and therapeu-tic strategies, particularly for at-risk populations.
- 8 July 2025
- Published by MDPI AG in Preprints.org
Open AccessUpdate on the Thromboembolic Events After Vaccination Against COVID 19
The association between COVID-19 vaccination and thromboembolic events has gar-nered significant research attention, particularly with the advent of vaccines based on adenoviral vectors, including AstraZeneca's and Johnson & Johnson's. This review un-derscores the uncommon occurrence of blood clotting events, including venous throm-boembolism (VTE), arterial thromboembolism (ATE), and vaccine-induced thrombotic thrombocytopenia (VITT), following COVID-19 vaccination. Although these complica-tions are extremely rare compared to the heightened risk of thrombosis from COVID-19 infection, elements like age, biological sex, type of vaccine and underlying health conditions may contribute to their development. Current guidelines emphasize early detection, individualized risk assessment, and the use of anticoagulation therapy to mitigate risks. Despite these rare events, the overwhelming evidence supports the con-tinued use of COVID-19 vaccines, given their proven efficacy in reducing severe illness and mortality. Ongoing research is essential to further refine preventive and therapeu-tic strategies, particularly for at-risk populations.
- 14 February 2025
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 83 (4) , 427-435
Environmental degradation. An under-recognized secondary risk factor of hypertension
- 14 February 2025
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 83 (4) , 427-435
Environmental degradation. An under-recognized secondary risk factor of hypertension
- Open Access
The Optimal Management of Patients with Atrial Fibrillation and Acute Heart Failure in the Emergency Department
Atrial fibrillation (AF) and acute heart failure (AHF) are two closely interrelated conditions that frequently coexist in a manifold manner, with AF serving either as the causative factor or as the consequence or even as an innocent bystander. The interplay between these two clinical conditions is complex, given that they share common pathophysiological pathways and they can reciprocally exacerbate each other, thus triggering a vicious cycle that worsens the prognosis and increases the thromboembolic risk. The optimal management of AF in the context of AHF in the emergency department remains a challenge depending on the time onset, as well as the nature and the severity of the associated symptoms. Acute rate control, along with early rhythm control, when indicated, and anticoagulation represent the main pillars of the therapeutic intervention. The purpose of this review is to elucidate the pathophysiological link between AF and AHF and accordingly present a stepwise algorithmic approach for the management of AF in AHF patients in the emergency setting.
Open AccessThe Optimal Management of Patients with Atrial Fibrillation and Acute Heart Failure in the Emergency Department
Atrial fibrillation (AF) and acute heart failure (AHF) are two closely interrelated conditions that frequently coexist in a manifold manner, with AF serving either as the causative factor or as the consequence or even as an innocent bystander. The interplay between these two clinical conditions is complex, given that they share common pathophysiological pathways and they can reciprocally exacerbate each other, thus triggering a vicious cycle that worsens the prognosis and increases the thromboembolic risk. The optimal management of AF in the context of AHF in the emergency department remains a challenge depending on the time onset, as well as the nature and the severity of the associated symptoms. Acute rate control, along with early rhythm control, when indicated, and anticoagulation represent the main pillars of the therapeutic intervention. The purpose of this review is to elucidate the pathophysiological link between AF and AHF and accordingly present a stepwise algorithmic approach for the management of AF in AHF patients in the emergency setting.
- 18 November 2021
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 24 (1) , 173-174
Persistent left superior vena cava: is it an incidental pathology detected during pacemaker implantation or one of the causes of sick sinus syndrome?—Authors’ reply
- 18 November 2021
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 24 (1) , 173-174
Persistent left superior vena cava: is it an incidental pathology detected during pacemaker implantation or one of the causes of sick sinus syndrome?—Authors’ reply
- 1 October 2021
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 30 (10) , 1435-1441
Pulmonary Embolism Prophylaxis in Patients With COVID-19: An Emerging Issue
- 1 October 2021
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 30 (10) , 1435-1441
Pulmonary Embolism Prophylaxis in Patients With COVID-19: An Emerging Issue